NEO
$8.27
NeoGenomics, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical compani...
Recent News
Will Medicare Coverage for PanTracer LBx Liquid Biopsy Shift NeoGenomics' (NEO) Diagnostic Narrative?
NeoGenomics, Inc. recently announced that its PanTracer LBx liquid biopsy test has received Medicare coverage under the MolDX Plasma-Based Genomic Profiling in Solid Tumors policy, allowing eligible patients with advanced solid tumors to access blood-based comprehensive genomic profiling performed in its CLIA-certified California laboratory. The decision not only widens access to a more than 500-gene, seven-day-turnaround test but also highlights how liquid biopsy is becoming more embedded...
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries.
3 Reasons to Avoid NEO and 1 Stock to Buy Instead
What a fantastic six months it’s been for NeoGenomics. Shares of the company have skyrocketed 48.3%, hitting $9.94. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call
NeoGenomics’ fourth quarter results were met with a negative market reaction, despite revenue and non-GAAP earnings per share surpassing Wall Street’s expectations. Management attributed the quarter’s performance to continued growth in next-generation sequencing (NGS) test volumes, robust adoption of new products, and a deliberate shift away from lower-value, high-volume testing. CEO Anthony Zook noted, “Our clinical business continued its robust growth with revenue increasing 16% year over year
Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness
Event context and recent share performance NeoGenomics (NEO) has been on many investors’ radars after a tough stretch in the share price, with negative returns over the past week, month and past 3 months adding to longer term weakness. See our latest analysis for NeoGenomics. At around US$9.89, NeoGenomics’ recent 7-day share price return of a 13.09% decline and year-to-date share price return of a 15.90% decline sit alongside a 1-year total shareholder return of a 10.90% decline, suggesting...